Skin cancer

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
12 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Kinase inhibitor 5 substances
Checkpoint inhibitor (PD-L1) 1 substance
PARP inhibitor 1 substance
Taxane 1 substance
Antimetabolite 1 substance
RAF/BRAF inhibitor 1 substance
BCL-2 inhibitor 1 substance
Unknown / small molecule 1 substance
Phase III: 1 Phase I: 1 Phase I (First in Human): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • F. Hoffmann-La Roche AG Commercial
    ALECTINIB; ALECTINIB HYDROCHLORIDE; ATEZOLIZUMAB; CABOZANTINIB; COBIMETINIB; NIRAPARIB; PACLITAXEL; PEMETREXED; SUNITINIB; VEMURAFENIB; VENETOCLAX
    2023-506184-34-00 11 countries 2019 n=104 Orphan
    Ended

Phase I

1 trial
  • Seagen Inc. Commercial
    IMP not specified
    2023-508469-34-00 2 countries 2020 n=238
    Recruiting

Phase I (First in Human)

1 trial
  • Novartis Pharma AG Commercial
    DYP688
    2023-509451-14-00 4 countries 2022 n=27
    Halted
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Seagen Inc. Commercial 1 Phase I 1
F. Hoffmann-La Roche AG Commercial 1 Phase III 0
Novartis Pharma AG Commercial 1 Phase I (First in Human) 0
New trials by year
2019
1
2020
1
2022
1
← All indication landscapes